AstraZeneca and Daiichi Sankyo announced positive high-level results from the DESTINY-Lung04 Phase III trial, marking a significant development in the treatment of non-small cell lung cancer. ENHERTU (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to the global standard of care. This makes it the first and only HER2-directed medicine to improve PFS over standard therapy in a Phase III trial for this specific patient population.

The trial evaluated ENHERTU as a first-line treatment for patients with unresectable, locally advanced or metastatic HER2-mutant non-squamous non-small cell lung cancer (NSCLC). The comparator arm consisted of platinum-pemetrexed doublet chemotherapy plus pembrolizumab, which represents the current global standard of care for these patients. Despite this robust combination therapy, many patients do not respond to first-line treatment and experience disease progression, highlighting the unmet need for more effective options.

Trial Context and Patient Population

Approximately 2-4% of patients with NSCLC have tumors with a HER2 mutation. For these individuals, the current standard of care involves a combination of immunotherapy and platinum-based chemotherapy. The DESTINY-Lung04 results suggest that targeting the HER2 mutation directly with ENHERTU offers a superior alternative in terms of delaying disease progression.

Next Steps

The trial will continue as planned to evaluate secondary endpoints, including overall survival. This ongoing data collection will provide further insight into the long-term efficacy and safety profile of ENHERTU in this patient group. The companies did not disclose specific numerical data for the hazard ratio or median PFS duration in this initial high-level announcement.

What the Numbers Show

While specific numerical outcomes were not disclosed, the characterization of the PFS improvement as both "statistically significant" and "clinically meaningful" indicates a robust separation between the treatment and control arms. Given that the standard of care already includes potent immunotherapy (pembrolizumab), achieving superiority over this benchmark suggests a strong mechanistic advantage for HER2-directed therapy in this specific molecular subset.

AstraZeneca and HUTCHMED have reported positive high-level results from the SAFFRON Phase III clinical trial, demonstrating that the combination of TAGRISSO (osimertinib) and savolitinib delivers significant survival benefits for patients with epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). The trial established statistical significance in both progression-free survival (PFS) and overall survival (OS) when compared against doublet platinum-based chemotherapy.

The study focused on a specific patient population with tumors exhibiting high levels of MET overexpression or amplification who had previously progressed on TAGRISSO treatment. This addresses a critical unmet need, as approximately one in three patients develop MET-driven resistance to third-generation EGFR-tyrosine kinase inhibitors (TKIs), a mechanism associated with poor prognosis.

Trial Context and Clinical Significance

Third-generation EGFR-TKIs have markedly improved outcomes for EGFRm NSCLC patients. However, MET overexpression or amplification remains one of the most common mechanisms of resistance. The SAFFRON trial is noted as the first global Phase III study to demonstrate significant benefits in both PFS and OS in this specific setting. These results reinforce the position of TAGRISSO as a backbone therapy across EGFRm lung cancer treatments.

The safety profile observed for the combination was consistent with the known profiles of each individual medicine, with no new safety findings reported. The data are scheduled to be presented at a forthcoming medical meeting and will be shared with global regulatory authorities.

Regulatory Status and Development

TAGRISSO plus savolitinib holds regulatory approval in China for patients with locally advanced or metastatic EGFRm NSCLC featuring MET amplification after disease progression on EGFR-TKI therapy. This approval was granted based on data from the SACHI Phase III trial. Savolitinib is being jointly developed by AstraZeneca and HUTCHMED, with AstraZeneca handling commercialization.